Of note, the topical application of PARPi-FL in 12 patients with oral cancer was well-tolerated with no adverse events in a phase 1 clinical trial (NCT03085147) with a tumor-to-margin ratio of > 3 at 1 μM [42], rendering PARPi-FL a very good candidate to implement FME in the surveillance of BE patients. This evidence concerns the gene FLT3LG and lip and oral cavity carcinoma.